Jean Jacques Bienaime - 09 May 2024 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Role
Director
Signature
/s/ Tae Sang Yoo, Attorney-in-Fact
Issuer symbol
BMRN
Transactions as of
09 May 2024
Net transactions value
-$731,200
Form type
4
Filing time
13 May 2024, 15:57:27 UTC
Previous filing
15 Apr 2024
Next filing
21 May 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BMRN Common Stock Options Exercise $1,262,000 +20,000 +4.2% $63.10 494,994 09 May 2024 Direct F1
transaction BMRN Common Stock Sale $1,632,400 -20,000 -4% $81.62 474,994 09 May 2024 Direct F1
transaction BMRN Common Stock Options Exercise $1,262,000 +20,000 +4.2% $63.10 494,994 10 May 2024 Direct F1
transaction BMRN Common Stock Sale $1,622,800 -20,000 -4% $81.14 474,994 10 May 2024 Direct F1
holding BMRN Common Stock 247,333 09 May 2024 Shares held by Jean-Jacques Bienaime Family Trust
holding BMRN Common Stock 100 09 May 2024 Shares held as UTMA custodian for child 1
holding BMRN Common Stock 100 09 May 2024 Shares held as UTMA custodian for child 2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BMRN Stock Option (Right to Buy Common Stock) Options Exercise $0 -20,000 -22% $0.000000 71,000 09 May 2024 Common Stock 20,000 $63.10 Direct F2
transaction BMRN Stock Option (Right to Buy Common Stock) Options Exercise $0 -20,000 -28% $0.000000 51,000 10 May 2024 Common Stock 20,000 $63.10 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Trade made pursuant to a 10b5-1 plan executed on August 7, 2023.
F2 Reflects the number of options outstanding after the transactions from this specific stock option grant.